Brief: Uppsala University Hospital And Sana Biotechnology Announce Authorization
Nov 17 (Reuters) - Sana Biotechnology Inc SANA.O :
* UPPSALA UNIVERSITY HOSPITAL AND SANA BIOTECHNOLOGY
ANNOUNCE
AUTHORIZATION OF THE FIRST-IN-HUMAN CLINICAL TRIAL APPLICATION
FOR A PRIMARY ISLET CELL TREATMENT FOR PATIENTS WITH TYPE 1
DIABETES
* SANA BIOTECHNOLOGY INC - GOAL IS TO REPORT UP421 PROOF OF
CONCEPT DATA IN 2023 AND 2024
Source text for Eikon: ID:nGNXbBHh8K
Further company coverage: SANA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sana Biotechnology
See all newsSana Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Sana Biotechnology Q2 adjusted loss narrows, beats estimates
Brief: Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15
Sana Biotechnology posts Q1 adjusted loss narrower than expected, extends cash runway
Brief: Sana Biotechnology Q1 Adjusted EPS USD -0.14 Vs. IBES Estimate USD -0.17